No-swimming advisories at 8 Metro Vancouver beaches
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace
The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI and decentralized trials. However, challenges persist with high operational costs and regulatory complexities. The market is vibrant, driven by rising clinical trial investments in sectors like oncology and enabled by innovative technologies, making it a promising field despite ongoing hurdles. North American Clinical Trials Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous government R&D spending. The growing need for novel medicines in a variety of therapeutic areas, including neurology, cardiology, and oncology, is the main factor propelling the North American clinical trials market's constant expansion. As a market leader, the United States enjoys the advantages of strong infrastructure, top-notch research facilities, and substantial investments in innovative healthcare. Drug development procedures are becoming faster and more efficient because to technological developments like big data, artificial intelligence, and decentralized clinical trials. Government financing and support for clinical research also contribute to the market's expansion. Nonetheless, the sector is still affected by issues including regulatory barriers, trouble recruiting patients, and expensive trial operating expenses. The market is nevertheless vibrant and is anticipated to continue evolving in spite of these market will expand quickly as a result of the growing number of clinical trials in North America, the pharmaceutical industry's expensive R&D costs, and the rising incidence of illnesses. Clinical trials for new or uncommon diseases are anticipated to benefit from the diverse disease profiles that are found to be growing with time due to the growing population in the North American region. Therefore, biopharmaceutical companies would be encouraged to increase their investment in clinical trials for a particular disease segment based on the number of patients with that of September 2022, there were over 13,323 ongoing clinical studies in various stages for cancer indications in the US, according to the US National Library of Medicine. Over the past few years, pharmaceutical corporations have likewise been spending more and more on research and development (R&D). This was mostly caused by a large number of patents expiring, which leaves many pharmaceutical companies with no choice except to create new medications. As a result, businesses are investing more in R&D to speed up the creation of medications through clinical trials, which will increase the market as a Drivers for the North America Clinical Trials Market Rising Prevalence of Chronic DiseasesOne of the main factors propelling the North American clinical trials market's expansion is the growing incidence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials are being conducted by pharmaceutical corporations and research institutions due to the growing demand for new treatments and therapies as these diseases proliferate. These studies are essential for assessing the efficacy and security of possible treatments. Clinical trials are crucial for expanding medical knowledge and enhancing patient outcomes since chronic diseases frequently call for long-term management and innovative treatment choices. An older population, which is more likely to suffer chronic illnesses, supports this trend and increases the need for ongoing clinical research and innovative therapy in TechnologyTechnological developments are drastically changing the clinical trials environment in North America. Clinical study design, management, and execution are being improved by emerging technologies including artificial intelligence (AI), machine learning (ML), and big data analytics. These technologies aid in the real-time analysis of massive volumes of trial data, the more accurate identification of qualified applicants, and the prediction of patient outcomes. They thereby shorten trial durations, cut down on mistakes, and enhance decision-making. AI and ML are also being used to remotely monitor patient adherence and optimize protocol design, which lowers costs and increases trial efficiency. These developments make technology a potent growth engine in the dynamic clinical research environment since they not only speed up drug development but also increase trial success Investment in Oncology ResearchOne of the main factors propelling the growth of the clinical trials market is the rising incidence of cancer in North America, which has greatly increased funding for oncology research. The creation of novel cancer treatments is receiving a significant amount of support from public and private institutions as well as pharmaceutical firms. Clinical trials focusing on cancer, such as immunotherapies, targeted medicines, and personalized medical methods, have increased as a result of this financial boom. Research efforts have been sped up by the need to find efficient treatments and raise survival rates, which has prompted quicker trial initiation and increased cooperation between sponsors and research institutes. Since cancer is still one of the top causes of mortality, the region's clinical trial activity is growing in scope and size due to the strong emphasis on oncology in the North America Clinical Trials Market High Operational CostsOne major issue facing the clinical trials sector in North America is high operating costs. Significant costs are associated with conducting a clinical trial, such as hiring highly qualified personnel, investing in cutting-edge technology, building out the facility, adhering to regulations, and continuously gathering and tracking data. Complex trial designs, multi-site coordination, and longer study durations can all result in further increases in these expenses. Financial limitations can make it difficult for smaller biotech companies and research institutes to start or continue trials, frequently forcing them to rely on collaborations or outside funding. There is still a lot of pressure to strike a balance between cost effectiveness, data quality, and legal requirements. The cost of trials only goes up as they get more creative and customized, which is a major obstacle to larger research and development ComplexitiesOne of the biggest obstacles facing the clinical trials sector in North America is the complexity of regulations. To guarantee the safety and effectiveness of novel medications and therapies, organizations such as the U.S. Food and Drug Administration (FDA) implement strict and ever-changing regulations. Although these rules are necessary, following them can cause delays in trial approvals and raise compliance expenses dramatically. The procedure, which can be time- and resource-intensive, entails thorough documentation, ethical evaluations, and adherence to stringent criteria. Conducting multinational or multi-site studies also adds another level of complexity because different regulatory requirements in different locations need to be carefully maintained. These elements may cause delays in the start of trials, cause schedule disruptions, and increase the administrative load on sponsors and research institutions. Key Players Analyzed: Overviews, Key Persons, Recent Developments, Revenue ICON Plc Wuxi AppTec SGS SA Syneos Health PRA Health Sciences Inc Pfizer Inc. IQVIA Medpace Stryker Corporation Zimmer Biomet Holdings Orthofix Medical Inc. NuVasive Inc. Globus Medical Inc. Bejo Zaden BV Corteva Agriscience Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $20.07 Billion Forecasted Market Value (USD) by 2033 $33.91 Billion Compound Annual Growth Rate 6.0% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Clinical Trials Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Phases6.2 By Indications6.3 By Study Designs6.4 By Countries7. Phases7.1 Phase 17.2 Phase 27.3 Phase 37.4 Phase 48. Indications8.1 Autoimmune/Inflammation8.2 Pain management8.3 Oncology8.4 CNS Condition8.5 Diabetes8.6 Obesity8.7 Cardiovascular8.8 Others9. Study Designs9.1 Interventional9.2 Observational9.3 Expanded Access10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Clinical Trials Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Women over 50, read this: 10 health problems you should have on your radar — and what to do about them
Health risks for females typically increases even further after menopause. Feel like you're a young 50? While many older Canadians report feeling younger mentally and physically than their age, once you hit 50, certain health issues can sneak up on you — no matter how good you feel. 'As we age, our cells naturally wear down, as do the systems that repair them. It's like your body's maintenance crew gets a little tired and understaffed,' explains Dr. Angela Downey, family physician and host of the "Codependent Doctor" podcast. 'This makes us more vulnerable to things like high blood pressure, diabetes, heart disease and certain cancers, even if we've lived a healthy life until this point.' While this is the case for everyone, being a woman comes with a few extra health risks. 'After menopause, estrogen levels drop, which increases the risk of heart disease, autoimmune conditions, vaginal dryness, urinary incontinence and osteoporosis,' Downey adds. This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. Knowledge is power, the old adage goes, so we're digging into the 10 different health problems that should be on your radar if you're a woman over 50 — plus how to stay on top of them. 10 health problems every woman over 50 should know — and what to do about them 1. Vision problems Vision changes are a known byproduct of getting older, but lower estrogen levels after menopause can also affect your eye health and lead to a need for glasses or a stronger prescription, reduced night vision and even a higher risk of eye conditions like dry eye and macular degeneration. You can stay on top of your eye health by having regular eye exams. Even if you have no vision issues, it's recommended you get an eye exam every two to three years if you're under 40, and every two years if you're over 40. Once you hit 65? Optometrists advise a yearly visit to stay on top of your ocular health. And of course, if you notice any sudden vision changes or physical changes to one or both of your eyes, head to the eye doctor as soon as possible. 2. Hearing loss Hearing loss is more common in men than women, but don't let that keep you from scheduling a hearing test. Around 54 per cent of Canadians aged 40 to 79 have mild hearing loss — but it can be quite sneaky. A lot of people who suffer from it don't even notice an issue. You may feel like your ear is a bit clogged or only have trouble hearing in noisy places. Even if the symptoms aren't impacting your daily life, it's important to have your hearing checked if you're over 50 or notice a change. It's not just age that can cause hearing loss; injuries, illness and certain medications can mess with your hearing, too. 3. Heart disease According to the Heart & Stroke Foundation of Canada, heart disease and stroke is the number one cause of premature death of women in Canada. Even more concerning? A whopping 89 per cent of women don't know their unique risk factors, many of which increase with age and/or menopause, such as high blood pressure and high cholesterol, obesity, diabetes and depression. Making heart-healthy lifestyle changes and seeing your doctor or pharmacist for regular blood pressure, cholesterol and blood sugar monitoring can help you keep your ticker healthy. 4. Osteoporosis Bone loss accelerates after menopause, increasing the risk of osteoporosis, and one in three women break a bone due to the condition, according to Osteoporosis Canada. Your sex and age aren't the only risk factors; family history, certain medications and your diet also play a role. Engaging in regular exercise, especially weight-bearing exercise, getting enough calcium and vitamin D and not smoking can help you reduce your risk. If you've ever fractured a bone, have a family history of osteoporosis, or are post-menopausal, ask your doctor about screening. 5. Autoimmune diseases When it comes to autoimmune diseases, the odds are stacked against women. Around 80 per cent autoimmune diseases are diagnosed in women — and the risk of developing one increases after menopause, according to Downey. There are more than 100 autoimmune diseases, including rheumatoid arthritis, lupus and thyroid diseases. Symptoms such as fatigue, joint pain and digestive issues can overlap with other conditions, and there's no single definitive test for all of them, making diagnosis tricky. If you notice new symptoms, see your doctor for appropriate testing. 6. Cancer A whopping nine in 10 cancers in Canada are diagnosed in people over the age of 50 — and aging is the most important risk factor for cancer. While this is true for males and females, there are some cancers that only or predominantly affect females, including cervical, breast, endometrial and ovarian cancers. Lung cancer, which once mostly affected men, is now affecting more women. Family history, age of your first period and number of pregnancies are just a few of the factors that affect a woman's risk of cancer. Talk to your doctor about your risk factors and screening. 7. Obesity About 65 per cent of Canadians are overweight or obese, most of them between ages 40 and 69. Slower metabolism less activity and hormonal shifts — especially during perimenopause, which causes an average weight gain of 4.5 pounds — are contributing factors. Staying active and eating well can help, but if needed, there are other tools available that may be worth discussing with your health-care provider. 8. Vaginal dryness Vaginal aging is a thing. As we — and our vaginas — get older, lower estrogen levels cause our once moist and flexible vaginal tissues to the become drier, thinner and less stretchy. Whether you're having sex or not, treating vaginal dryness is important because if left untreated, it can lead to symptoms like irritation and microtears, which can in turn increase your risk of infections. Vaginal dryness can be managed with over-the-counter treatments like vaginal moisturizers and lubricants. If those don't work, your health-care provider can prescribe topical estrogen, which is available in Canada in cream or tablet form. 9. Urinary tract infections (UTIs) Female anatomy — and having the urethra and anus in such close quarters — is to blame for females experiencing far more UTIs than men because it makes getting bacteria from one opening to the other a lot easier. After menopause, the risk increases due to skin irritation and tears from vaginal dryness and a decrease in good vaginal bacteria, which lets the less helpful bacteria grow. UTIs can lead to infections higher in the urinary tract, such as the bladder or kidneys, which can have serious complications. Treating vaginal dryness (see above) can help reduce the risk of UTIs. If you suspect you have a UTI, a doctor or pharmacist can prescribe antibiotics to treat it. 10. Urinary incontinence Urinary incontinence can happen to anyone, but it's most common in women over 50. That said, don't pass it off as a regular part of aging, as it can have several causes, some of which are treatable. Along with lower estrogen levels which can affect vaginal and urethral tissues, pelvic floor damage from giving birth, UTIs and certain medical conditions and medications are a few potential causes. If you're suddenly leaking urine, even if just a little, don't hesitate to reach out to your health-care provider.
Yahoo
6 hours ago
- Yahoo
Doctors brace for potential measles surge in Calgary as Alberta's outbreaks drag on
Health experts are keeping a close eye on the measles situation in Calgary as case counts tick up and they're warning that vigilance is key. With a new case reported in the Calgary health zone on Friday, the number of confirmed cases has nearly doubled in about a month after remaining relatively low and stable for several months. As of midday Friday, the zone accounted for 44 of the province's 1,538 confirmed cases this year. "We have more to come and I think that this is the tip of the iceberg," said Dr. Tania Principi, a pediatric emergency physician and associate clinical professor at the University of Calgary's Cumming School of Medicine. She's seeing an increase in Calgary children with measles. And they can be very sick, she warned. "A lot of these kids get quite significant pneumonias, trouble breathing. They've needed to go to the ICU," she said. "Measles is dangerous. People can die from it.... You can have brain damage from it. So it's not just like a cold." Measles is highly contagious and can hang in the air for several hours after a person leaves a location. The virus can lead to serious complications including pneumonia, brain inflammation, premature delivery and even death. And there is no treatment for measles, according to Principi. "I'm worried, to be honest.... People start spreading measles even before they know they have it," she said. She expects to see a bigger surge in the coming weeks. "With festivals,... people travelling and vacation, I anticipate that we're going to see a lot more measles especially in Calgary, but throughout the province, [through] the summer and as kids go back to school in the fall," said Principi. "The only way we can stop the spread is ensuring that people are vaccinated and if people do have symptoms that they stay home. But otherwise unfortunately this is going to continue to spread and our numbers are going to continue to increase." Vaccination rates "My level of concern is very high. And Calgary, and the north, are at the top of that concern," said Dr. James Talbot, a former chief medical officer of health for Alberta. He made the comments in response to a question from CBC News at a recent expert panel hosted by the Alberta Medical Association. While the north and south health zones continue to be the hardest hit parts of the province, Talbot sees worrying signs in Calgary. Some of the locations identified in the most recent Alberta Health Services measles exposure advisories include the emergency department at Alberta Children's Hospital, the ER at South Health Campus and the Glenmore Landing location of Alberta Precision Laboratories. "Calgary has amongst the better immunization rates in this age group, but it's well below the 95 per cent that's required for protection." According to provincial data, 74 per cent of children in the Calgary zone who turned two years old in 2024 were up-to-date with two doses of the measles vaccine. The provincial average was 68 per cent. That vaccination rate has, so far, prevented community-level transmission, according to the University of Calgary's Craig Jenne. "Because we're not truly at herd immunity, there is a risk that the virus can find an under-vaccinated population in the city and maintain some spread," said Jenne, a professor in the department of microbiology, immunology and infectious diseases. "We have to be quite aware of that and hopefully we can stay on top of contact tracing, exposure alerts and anybody that may be at risk of contracting measles, and has been exposed, can self-isolate and get help as needed to really reduce the risk of this getting a foothold in the city." Jenne said a lot of the cases in Calgary appear to be travel-related because locations such as hotels and the airport have been included in AHS exposure alerts. The more cases that are brought into the city, the more likely the virus will find under-vaccinated groups and spark more widespread transmission in Calgary, he warned. "Unfortunately the more times it's challenged, the more cases that appear, the more likely it is the virus will find a little daylight and be able to spread," said Jenne, who's also the deputy director of the Snyder Institute for Chronic Diseases. Visitor restrictions Meanwhile, visitor restrictions are in place at some Alberta hospitals now, as health officials work to reduce the risk of measles spreading to vulnerable patients. Alberta Health Services (AHS) said temporary limits can be put in place in locations including pediatric hospitals, cancer treatment sites, labour and delivery units, as well as neonatal intensive care units and pediatric intensive care units AHS says it's up to zone leadership to decide on a case-by-case basis whether to implement these restrictions and compassionate exemptions will be considered. "As the measles situation continues to be dynamic, this approach allows zone leadership to determine whether restrictions are needed to support the well-being of patients," spokesperson Kristi Bland said in a statement emailed on Friday. "In areas such as Edmonton and Calgary, where measles cases currently remain low, these precautions may be implemented due to the potential risk posed by visitors from regions with substantial measles circulation. They are not a response to increased risk or transmission within Calgary or Edmonton." AHS has so far not specified to CBC News which hospitals have actually put these measures in place.
